FDA approves update of the product label for Zilretta for treatment of osteoarthritis knee pain.- Flexion Therapeutics
Related news and insights
Ampio Pharmaceuticals, Inc. announced positive data from the modified Intent-to-Treat (mITT) population in the Company’s AP-013 study, a Phase III clinical trial of the company’s lead candidate, Ampion, in patients suffering from severe osteoarthritis of the knee (OAK).
Merck KGaA, a leading science and technology company, has, through its subsidiary Ares Trading S.A., entered into an out-licensing agreement for sprifermin with TrialSpark/High Line Bio, New York, USA.
Ampio Pharmaceuticals announced top-line results from AP-013, a randomized, saline-controlled, double-blind Phase III clinical study evaluating the efficacy of an intra-articular (IA) injection of Ampion in adults with pain due to severe osteoarthritis of the knee (OAK) .